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2Abstract
The elucidation of the transcriptional mechanisms that regulate glial fibrillary acidic
protein (GFAP) gene expression is important for the understanding of the molecular
mechanisms that control astrocyte differentiation during brain development. We
investigated regulatory elements located in a proximal region of the GFAP promoter
important for expression in cortical precursor cells differentiating into astrocytes. One
of these elements recognizes transcription factors of the Nuclear Factor-I family (NFI).
We found that in primary cultures of cortical cells NFI occupies the GFAP promoter
prior to the induction of astrocyte differentiation. In the developing cerebral cortex the
onset of expression of NFI coincides chronologically with the beginning of
astrocytogenesis. Mutational analysis of the GFAP gene and transfections in primary
cortical precursors show that inhibition of binding of NFI to the GFAP promoter results
in decreased levels of transcriptional activity and is required for the synergistic
stimulation of the GFAP promoter by the astrogenic agents pituitary adenylate cyclase-
activating polypeptide and ciliary neurotrophic factor, which in combination enhance
astrocyte differentiation to generate astrocytes with longer processes. Thus, NFI
appears to be an important factor for the integration of astrogenic stimuli in the
developing central nervous system.
Keywords: astrocyte differentiation, pituitary adenylate cyclase-activating polypeptide,
ciliary neurotrophic factor, transcription factors, neural progenitor cells, process
outgrowth.
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3INTRODUCTION
Neural progenitor cells that proliferate in the embryonic central nervous system
respond to specific extracellular signals that determine their differentiation into neurons
or glial cells (Gross et al. 1996; Johe et al. 1996; Bonni et al. 1997; Park et al. 1999). In
the case of astrocytes, expression of glial fibrillary acidic protein (GFAP) constitutes a
cell-specific phenotypic hallmark of their identity. The restrictive expression of GFAP
in astrocytes indicates the requirement of specific combinations of transcription factors
assembled on the GFAP gene promoter that occur only in this type of cells. Therefore,
the elucidation of the transcriptional mechanisms that stimulate GFAP gene expression
in a cell-specific manner is important for the understanding of how phenotypic
transitions take place during the differentiation process that generates astrocytes in the
developing nervous system.
At least three major signaling pathways that promote the generation of
astrocytes in the central nervous system have been identified. One relies on the
phosphorylation of intracellular JAK and STAT proteins to activate GFAP gene
expression in response to stimulation by ciliary neurotrophic factor (CNTF) (Johe et al.
1996; Bonni et al. 1997; Koblar et al. 1998; Rajan and McKay 1998). Another one is
activated by some bone morphogenetic proteins (Gross et al. 1996; Nakashima et al.
2001), that act via intracellular activation of Smad proteins (Ebendal et al. 1998; Zhang
et al. 1998). A third mechanism relies on the synthesis of cAMP elicited in fetal
cerebrocortical precursor cells by pituitary adenylate cyclase-activating polypeptide
(PACAP), thus triggering GFAP gene expression and promoting astrocyte
differentiation (McManus et al. 1999; Vallejo and Vallejo 2002).
Stable expression of GFAP in astrocytes requires permanent chromatin
remodeling to allow the formation of cell-specific combinations of transcription factors
4assembled on the GFAP promoter (Song and Ghosh 2004). As the onset of astrocyte
differentiation is accompanied by the stimulation of GFAP gene expression, a number
of studies have been carried out to investigate how transcriptional mechanisms that
induce expression of this gene, silent in neurons and in undifferentiated neural
precursors, are activated. These studies have led to the identification of several DNA
cis-regulatory elements present in the promoter regions of the human, mouse and rat
GFAP genes. Transcription factors that activate GFAP gene expression by acting on
these sites include AP-1 (Masood et al. 1993; Barnett et al. 1995), STAT and Smad
proteins (Bonni et al. 1997; Kahn et al. 1997; Rajan and McKay 1998; Nakashima et al.
1999; Sun et al. 2001; Rajan et al. 2003), steroid hormone receptors (Stone et al. 1998),
and proteins activated by TGF-b1 (Krohn et al. 1999). In addition, activation of GFAP
gene expression requires cell-specific CpG site demethylation (Takizawa et al. 2001).
Despite these advances, a detailed knowledge of the molecular mechanisms that
regulate the stable expression of GFAP in astrocytes is still missing. In the present
study, we demonstrate that binding of Nuclear Factor-I (NFI) to a specific site in the rat
GFAP gene promoter is required for optimal GFAP gene expression in cortical
precursor cells induced to differentiate into astrocytes by exposure to PACAP and
CNTF.
MATERIALS AND METHODS
Reagents - Radioactive compounds were obtained from Amersham Biosciences.
Nucleotides were purchased from Promega. Tissue culture medium and reagents were
obtained from Life Technologies Inc. Basic fibroblast growth factor (bFGF) and CNTF
were from PeproTech EC Ltd. (London, England). PACAP-38 and all other reagents
were obtained from Sigma Chemical Co. (Madrid, Spain) unless otherwise specified.
5Plasmids - Luciferase reporter plasmids bearing 5'-flanking sequences of the rat GFAP
gene promoter (Bonni et al. 1997; Krohn et al. 1999) were kindly provided by Dr. Irina
Rozovsky (University of Southern California, Los Angeles). The longest fragment used
(GFAP-A7Luc) corresponds to nucleotides -1546 to +13, relative to the transcription
initiation site (Condorelli et al. 1994), and the rest of them (GFAP-A6Luc to GFAP-
A2Luc) correspond to smaller fragments generated by sequential 5' deletions (Fig. 1).
An additional plasmid, GFAP-A9Luc was constructed. For this purpose a synthetic
double stranded oligonucleotide with KpnI and BglII sites at the 5’ and 3’ ends,
respectively, corresponding to a GFAP minimal promoter (nucleotides –35 to +13), was
inserted into the plasmid pGL2-Basic (Promega).
The plasmids GFAP-A7MutBLuc and GFAP-A7MutCLuc were generated by
oligonucleotide directed mutagenesis using GFAP-A7Luc as a template. For this
purpose, we used Pfu Turbo DNA polymerase from a QuikChange (Stratagene) site-
directed mutagenesis kit following the instructions provided by the manufacturer.
Template DNA was eliminated by digestion with DpnI. GFAP-A7MutBLuc
incorporates a four-bp mutation between nucleotides –71 and –68, and GFAP-
A7MutCLuc incorporates a four-bp mutation between nucleotides –65 and –62. The
sequences of the oligonucleotide primers containing the four base mismatches are as
follows: MutB, 5’-TGGGGTGCCATTAGGAAGTCAGGG-3’; and MutC, 5’-
GGGGTGCTGCCAGAGGATCAGGGGCAGA-3’.
Cell culture and transfections - RC2.E10 cells derive from rat E16 fetal cortex and
express GFAP when exposed to 8Br-cAMP (Schwartz and Vallejo 1998; McManus et
al. 1999). These cells were cultured in DMEM containing 10% fetal bovine serum, at a
6temperature of 33 ºC and were transfected with Lipofectin (Life Technologies, Inc.) as
described (Schwartz and Vallejo 1998). After transfection, cells were cultured in the
presence of 1 mM 8Br-cAMP.
Primary cortical cell cultures from the cerebral cortex from fetal brains of E17
Wistar rats were prepared as described (Vallejo and Vallejo 2002). Briefly, cell
suspensions prepared by trituration of the dissected fetal cortex were washed and
resuspended in serum-free DMEM containing N1 supplement (Sigma) and 1mM
sodium pyruvate (defined medium) (Bottenstein and Sato 1979), to which bFGF (20
ng/ml) was added. Cells were seeded into poly-ornithine-coated 10-cm dishes at a
density of 2-4 x 104 cells/cm2, and were expanded at 37°C for 3-4 days. Medium was
replaced every two days.
For differentiation experiments, cells were plated into 35 mm dishes at a density
of 4 x 104 cells/cm2. After incubation at 37°C for 24 hours, bFGF-containing medium
was replaced with bFGF-free defined medium, and PACAP (1-100 nM) and/or CNTF
(1-50 ng/ml) were immediately added. After the addition of these compounds cells were
incubated for 2 days, at the end of which they were processed for
immunocytochemistry.
For transfections, 106 cells/plate were seeded into poly-ornithine-coated 60 mm
dishes in defined medium in the presence of bFGF (20 ng/ml). After an overnight
incubation, the medium was removed and 6 mg of reporter plasmid DNA mixed with 10
ml FuGENE 6 Transfection Reagent (Roche) were added in 4 ml defined medium and
incubated for 4 hours. After this, the medium-DNA mix was removed and substituted
with fresh defined medium, or with defined medium containing PACAP or CNTF at the
indicated concentrations.
7Luciferase activity was measured using a commercial assay system (Promega)
48 hours after transfection. Luciferase activity elicited after transfection of RSV-Luc
was used as an independent standard for normalization, and efficiencies were corrected
by using the Renilla luciferase assay system (Promega). All the values are expressed as
mean ± s.e.m. of at least three independent experiments carried out in duplicate.
Electrophoretic mobility shift assays (EMSA) - EMSA were carried out with nuclear
extracts (Schreiber et al. 1989), in the presence of the protease inhibitors pepstatin A (1
mg/ml), leupeptin (10 mg/ml), aprotinin (10 mg/ml) and p-aminobenzamidine (0.1
mM). Protein concentrations were determined by the Bio-Rad protein assay with bovine
serum albumin as a standard. Synthetic complementary oligonucleotides with 5' GATC
overhangs were annealed and labeled by a fill-in reaction using a-32P-dATP and
Klenow enzyme. Binding reactions were carried out in the presence of 2 mg of
poly(dI.dC) and competitor oligonucleotides as indicated, using nuclear extracts (10 mg
of protein) incubated with 20,000 cpm of radiolabeled probe (approximately 6 to 10
fmol) in a total volume of 20 ml containing 20 mM potassium phosphate (pH 7.9), 70
mM KCl, 1 mM DTT, 0.3 mM EDTA, and 10% glycerol. The sequences of the





Western blot - Nuclear extracts (Schreiber et al. 1989) from cerebral cortex of
developing rats or whole cell extracts from cultured primary cells were prepared and
8proteins (20 mg) were resolved by SDS-PAGE and blotted onto a nitrocellulose
membrane. NFI or CREB immunoreactivities were detected with rabbit polyclonal
primary antisera (Santa Cruz) used at 1:5000 or 1:2000 dilution, respectively, followed
by incubation with a goat anti-rabbit peroxidase-conjugated secondary antibody
(1:10,000 dilution) (BioRad, Hercules, CA). GFAP or b-actin immunoreactivities were
detected with specific monoclonal antibodies, (clone G-A-5, 1:10,000 dilution; and
clone AC-15, 1:5,000 dilution, respectively, Sigma) followed by incubation with a horse
anti-mouse peroxidase-conjugated secondary antibody (1:5,000 dilution) (BioRad,
Hercules, CA). Immunoreactive bands were visualized using an enhanced
chemiluminescence detection system (ECL, Amersham, Buckinghamshire, England).
Chromatin immunoprecipitation (ChIP) assays - ChIP assays were carried out
basically as descried by Gerrish et al. (2001). Subconfluent cultures of E17 cortical cells
were treated with 1% formaldehyde for 10 minutes at room temperature and the cross-
linked protein-DNA complexes were isolated. Chromatin was sonicated in a volume of
200 ml, and diluted in buffer containing 1% Triton X-100, 2 mM EDTA, 20 mM Tris-
HCl (pH 8.0), 150 mM NaCl and protease inhibitors. Immunoprecipitations were
carried out using an anti-NFI antiserum (N-20, Santa Cruz), or control normal rabbit
IgG (sc-2025, Santa Cruz), and antibody-protein-DNA complexes were isolated by
incubation with protein A-Sepharose. After extensive washing, the DNA was eluted and
detected by PCR using oligonucleotide primers that amplify a fragment of the GFAP
gene spanning nucleotides –220 to +51. PCR conditions were: 95 °C for 5 min,
followed by 30 cycles of 94 °C for 30 sec, 55 °C for 30 sec, and 72 °C for 30 sec, after
which a 5 min incubation at 72 °C followed. The sequence of the oligonucleotide
primers are: Forward, 5’-CCCTCTCCTGACCCATTTACCAGAA-3’; and reverse, 5’-
9GCCCCTGACCATCGTCTCGGAGGAG-3’. As a negative control, PCR was also
carried out using oligonucleotide primers that amplify a fragment of the somatostatin
gene spanning nucleotides –550 to –120. PCR conditions were: 95 °C for 5 min,
followed by 30 cycles of 94 °C for 30 sec, 55 °C for 30 sec, and 72 °C for 30 sec, after
which a 5 min incubation at 72 °C followed. The sequence of the oligonucleotide
primers are: Forward, 5’-GATTGGACAAAGTGATGCTC-3’; and reverse, 5’-
AGTGAGGGGAGGCGACAC-3’. As an additional control, GFAP ChIP assays were
carried out in non-GFAP-expressing Rat-1 fibroblasts. PCR products were run on a 1%
agarose gel, stained with ethidium bromide, and photographed.
Immunocytochemistry and digital image analysis - GFAP immunocytochemistry was
carried out with cells plated into poly-ornithine-coated 35 mm tissue culture dishes,
using a specific monoclonal antibody (1:300 dilution) (clone G-A-5, Sigma) exactly as
described (Vallejo and Vallejo 2002). For the detection of NFI immunoreactivity, a
specific anti-NFI antiserum (Santa Cruz) was used at a 1:1000 dilution. In control
experiments, the antiserum was preincubated for 1 hour with a specific NFI blocking
peptide (Santa Cruz) used in a 5-fold molar excess. Immunodetection was carried out
using immunoperoxidase staining with a Vectastain ABC kit (Vector Laboratories).
For the determination of the length of astrocyte processes, GFAP-
immunostained cells were visualized on a Nikon microscope equipped with an Olympus
DP50 digital camera using a 20x objective. Measurement of the total length of the
processes in each GFAP-positive cell was carried out on digital images generated at the
image analysis core facility in our Institute using calibrated AnalySIS imaging software
(Soft Imaging Systems Gmbh, Münster, Germany). Three or four randomly selected
images per plate, taken from three independent experiments carried out in duplicate,
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were analyzed for each condition. The total number of cells analyzed range between
approximately 500 and close to 700, as indicated at the bottom of figure 9G.
Animals - Experimental protocols involving Wistar rats for the preparation of primary
cultures or protein extracts from nervous tissue were approved by the institutional
committee on research animal care, and meet the requirements of current Spanish and
European Community legislation.
RESULTS
Evaluation of transcriptional control regions by deletional analysis of the GFAP
promoter in neural cells - RC2.E10 cells constitute a phenotypically homogeneous
and stable monoclonal cell line that express GFAP and that have been used extensively
in transfection studies in our laboratory (Schwartz and Vallejo 1998; McManus et al.
1999; Schwartz et al. 2000; Pérez-Villamil et al. 2004). Thus, we initially used this cell
line to determine the approximate boundaries of transcriptional control regions that
regulate cell-specific GFAP gene expression.
Cells were transfected with the luciferase reporter plasmid GFAP-A7Luc,
spanning approximately 1.5 kb of the GFAP promoter, or luciferase reporter plasmids
generated by sequential 5’-deletions of the fragment in GFAP-A7Luc (Bonni et al.
1997). GFAP-A7Luc reporter activity was readily detectable in transfected RC2.E10
cells. As shown in Figure 1, a 5’ deletion of the GFAP promoter to nucleotide –1342
(GFAP-A6Luc) resulted in an increased luciferase activity by approximately two-fold.
In contrast, luciferase activity was significantly reduced when a plasmid with a deletion
to nucleotide –1049 (GFAP-A5Luc) was used (Fig. 1). However, more extensive
deletions to nucleotides –384 (GFAP-A3Luc) and –106 (GFAP-A2Luc) resulted in
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partial recovery and slight enhancement, respectively, of the transcriptional activity
relative to that observed with the full-length GFAP-A7Luc plasmid. Finally, the
luciferase activity observed in RC2.E10 cells transfected with a plasmid bearing a
deletion to nucleotide –35 (GFAP-A9Luc) was low and close to background levels (Fig.
1), indicating that the region spanning nucleotides –106 to –35 contains regulatory
elements that are sufficient to activate transcription of a similar magnitude to that
observed with the full-length promoter.
NFI recognizes the proximal promoter region of the GFAP gene - The proximal
promoter region identified in the transfection experiments includes a segment that
contains a sequence motif that coincides with the consensus binding site 5’-
TGG(N6)GCCA-3’ for NFI (Liu et al. 1997; Krohn et al. 1999; Rafty et al. 2002). This
site, spanning nucleotides –79 to –67, was found to be important for induction of GFAP
gene transcription by TGF-b1 and repression by interleukin-1b in primary astrocytes,
although binding of NFI was not demonstrated (Krohn et al. 1999).
To test for DNA-protein interactions in this region by EMSA, a double stranded
oligonucleotide spanning nucleotides –85 to –61 was synthesized. Incubation of this
oligonucleotide with nuclear extracts prepared from RC2.E10 cells resulted in the
generation of DNA-protein complexes whose specificity was determined by
competition with unlabeled oligonucleotide added in excess to the binding reaction or
with an oligonucleotide of unrelated sequence, that failed to compete (Fig. 2A).
These complexes were also competed when an oligonucleotide bearing a four-
base pair mutation located immediately 5’ to the NFI consensus binding site (Mutant A)
was used (Fig. 2B). In contrast, an oligonucleotide incorporating a four-base mutation
within the NFI binding site (Mutant B) failed to compete these complexes efficiently
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(Fig. 2B). Finally, we also used an oligonucleotide incorporating a four-base mutation
located immediately 3’ to the NFI consensus binding site (Mutant C). Addition of this
oligonucleotide resulted in partial competition, allowing the identification of a slower
migrating complex corresponding to proteins that bind immediately downstream from
the NFI consensus site (Fig. 2B).
To determine whether the identified complexes contain NFI proteins, we carried
out EMSA in the presence of two different anti-NFI antisera. One of these antisera
(anti-NFI/8199) recognizes an N-terminal region that is conserved within the DNA
binding and dimerization domains of all NFI isoforms (Gronostajski 2000), whereas the
other one (anti-NFI/2902) recognizes a segment of residues located within the C-
terminal region of the NFIC protein (Ortiz et al. 1999). Addition of the 8199 antiserum
resulted in the disappearance of the lower complex, indicating the presence of bound
NFI proteins (Fig. 2C). In turn, the addition of the 2902 antiserum resulted in the
disappearance of the same complex and the appearance of a supershifted band,
indicating that one of the NFI proteins recognized by the oligonucleotide in RC2.E10
cells corresponds to NFIC (Fig. 2C). Thus, these experiments indicate that the
nucleotides defined by mutant B are essential for binding of NFI proteins to this site.
To investigate the functional consequences of lack of binding of NFI to the
GFAP gene, we introduced mutations corresponding to the B or C sites in the context of
the full length promoter within the GFAP-A7Luc plasmid. Mutation of nucleotides
located within the NFI site resulted in a significant decrease in GFAP-A7Luc activity
(Fig. 2E, MutB). In contrast, mutation of nucleotides located downstream from the
consensus NFI binding site (MutC) did not alter significantly the luciferase activity
elicited by GFAP-A7Luc in transfected RC2.E10 cells (Fig. 2E). Thus, these
experiments support the notion that NFI is important for expression of the GFAP gene.
13
NFI is expressed by primary neural precursor cells from the developing cortex -
Since RC2.E10 cells are a clonal cell line originally immortalized with a viral
oncogene, they may not be necessarily representative of precursor cells that
differentiate into astrocytes in the developing brain (McManus et al. 1999). Therefore,
we sought to determine whether NFI is expressed in primary precursor cells from the
developing cortex, and whether it is important for the expression of GFAP in astrocytes
differentiated from these cells. Based on our previous work, we used PACAP as an
stimulus for the differentiation of astrocytes from cortical cells (McManus et al. 1999;
Vallejo and Vallejo 2002).
First, we investigated by immunocytochemistry the presence of NFI in cortical
precursor cells that differentiate into astrocytes. As shown in Fig. 3, we found NFI
immunoreactivity in the nuclei of primary cortical cells prepared from E17 rat brains
and cultured in defined medium in the presence of bFGF. We have previously
determined that these cells are proliferating, nestin-positive neuroepithelial precursors
(McManus et al. 1999; Vallejo and Vallejo 2002). Figure 3 also shows that NFI is
present in astrocytes differentiated from these neural precursors in response to exposure
to PACAP (100 nM) over two days. In both cases, comparison with images taken by
phase contrast microscopy showed that all cells were immunoreactive for NFI (Fig. 3).
Next, we sought to determine whether NFI present in primary neuroepithelial
precursor cells is functionally related to the stimulation of GFAP gene expression that
occurs when astrocytes differentiate. Thus, to determine whether NFI binds specifically
to cognate elements of the endogenous GFAP gene in the context of native chromatin in
vivo, we used ChIP assays. We found that the anti-NFI antiserum, but not control rabbit
IgG, immunoprecipitates from primary cortical precursor cells a fragment of
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formaldehyde cross-linked chromatin that contains the NFI binding site within the
proximal promoter region of the GFAP gene defined in our previous experiments (Fig.
4A). This immunoprecipitated fragment was detected both in primary cortical precursor
cells from E17 rat brains cultured in defined medium in the presence of bFGF, and in
astrocytes whose differentiation from these cells had been induced by withdrawal of
bFGF and treatment with PACAP (100 nM) for two days (Fig. 4A). In contrast, no
DNA amplification was obtained in samples immunoprecipitated from Rat-1
fibroblasts, which were used as non-GFAP-expressing control cells (Fig. 4B).
The onset of expression of NFI in the developing cortex coincides with the
beginning of astrogenesis - In the developing rat brain, cortical astrocytogenesis starts
at about E17 and proceeds postnatally (Jacobson 1993; Qian et al. 2000). To investigate
the existence of a possible relationship between the onset of astrogenesis and NFI
expression, we carried out western immunoblots using nuclear extracts prepared from
developing cerebral cortex obtained from E14 to E19 fetuses or from newborn rat pups.
We found that NFI immunoreactivity was practically undetectable in cortical cells from
E14 rats. In contrast, at E17 an immunoreactive band corresponding to NFI was clearly
detectable (Fig. 5A). NFI immunoreactivity was also detected in nuclear extracts
prepared from cerebral cortex of E19 and newborn rats (Fig. 5A). For comparison,
GFAP immunoreactivity was also determined in protein extracts from developing
cerebral cortex. As expected, GFAP was practically undetectable at E14, but was
clearly detectable with increasing intensity from E17 (Fig. 5A). Thus, expression of
NFI in the developing rat brain coincides chronologically with the onset of astrocyte
differentiation, and remains elevated during the time in which astrocytogenesis occurs.
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Nuclear extracts prepared directly from developing cerebral cortex were also
used in EMSA to assess the binding of nuclear proteins to the NFI site in the GFAP
gene promoter. Incubation of a 32P-labeled oligonucleotide including the NFI site of the
GFAP gene (nucleotides –85 to –61) with nuclear extracts prepared from E14 fetuses
yielded only a weak retarded band, indicating that at this time of development this site
is not efficiently recognized by nuclear proteins of the fetal cortex (Fig. 5B). In marked
contrast, incubation of E17 nuclear extracts resulted in the generation of DNA-protein
complexes that yield intensely labeled retarded bands. These complexes could also be
detected when nuclear extracts from cerebral cortex of E19 or newborn rats were used
(Fig. 5B). Thus, binding of nuclear proteins to the NFI site coincides with the increase
in NFI expression observed in developing cerebral cortex starting at around E17 and
extending to at least postnatal day 1.
Competition experiments using nuclear extracts from E17 rat cerebral cortex
showed that the integrity of the NFI consensus sequence is essential for binding of
nuclear proteins to this site. Thus, an oligonucleotide containing mutated nucleotides
outside and upstream from the NFI site (Mutant A) was able to compete as efficiently
as the wild type oligonucleotide, an oligonucleotide containing mutated nucleotides
within the NFI site (Mutant B) failed to compete completely, and an oligonucleotide
containing mutated nucleotides outside and downstream from the NFI site (Mutant C)
could only compete partially (Fig. 5C).
Finally, the addition of anti-NFI/8199 or anti-NFI/2902 antisera to the binding
reaction indicated that NFI proteins expressed in cells from the developing cortex are
present within the DNA-protein complexes assembled on the CRR probe (Fig. 5D).
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The NFI binding site is important for optimal GFAP promoter activity in
differentiating astrocytes - In order to investigate whether the NFI site is important for
GFAP gene expression during astrocyte differentiation, we carried out transient
transfections with GFAP-luciferase reporter plasmids, using primary cortical cells
obtained from E17 rat fetuses. GFAP gene expression was induced after transfections
by treatment with PACAP (100 nM) (Vallejo and Vallejo 2002) or with CNTF (30
ng/ml) (Johe et al. 1996; Bonni et al. 1997; Rajan and McKay 1998; Park et al. 1999)
for 48 hours.
GFAP-A7Luc basal activity was clearly detected above background levels and
represented approximately 1% of the activity elicited by RSV-Luc. Treatment of
transfected precursor cells with PACAP or with CNTF resulted in a 4-5 fold stimulation
of GFAP-A7Luc activity (Fig. 6), which reflects the observed astrocyte differentiation
induced by both agents in separate plates of cells, as monitored by
immunocytochemistry (not shown). When both PACAP and CNTF were administered
simultaneously on the same cells, GFAP-A7Luc activity was increased to higher levels
than those observed when each one of these factors was used alone (Fig. 6). This
combined effect was observed both with relatively low concentrations of PACAP (10
nM) and CNTF (10 ng/ml), and with the higher concentrations used (100 nM and 30
ng/ml, respectively) (Fig. 6). In this latter case, the effect of the combined treatment on
luciferase activity was not higher than the one observed when a low concentration of
PACAP (10 nM) was administered with a higher concentration of CNTF (30 ng/ml)
(Fig. 6).
Similar transfections were carried out using the GFAP-A7MutBLuc reporter,
which contains a four base mutation within the NFI site in the GFAP promoter. The
presence of this mutation in the NFI site resulted in significantly decreased basal levels
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of luciferase activity (Fig. 6). However, treatment of transfected cells with PACAP
stimulated the transcriptional activity of the mutated GFAP promoter, although the
luciferase activity elicited by this treatment only reached levels similar to those
exhibited by the unstimulated wild type promoter. Similarly, treatment with CNTF did
not result in levels of luciferase activity above those observed in basal conditions with
the wild type promoter (Fig. 6). Notably, when both agents were used simultaneously
on the transfected cells, the observed stimulation of luciferase activity from GFAP-
A7MutBLuc was not higher that those observed when either PACAP or CNTF were
added independently (Fig. 6).
Finally, transfection of the GFAP-A7MutCLuc reporter plasmid incorporating a
four base mutation immediately 3’ to the NFI binding site yielded luciferase levels that
were similar to those observed after transfections with the wild type promoter construct
(Fig. 6). In this case, treatment of transfected precursor cells with PACAP or with
CNTF resulted in a 2-3 fold stimulation of GFAP-A7MutCLuc activity (Fig. 6), and
when both PACAP and CNTF were administered together, this activity was further
increased to higher levels than those observed when each one of these factors was used
alone (Fig. 6).
PACAP and CNTF cooperate to stimulate GFAP expression synergistically in
differentiating astrocytes - The experiments described in figure 6 suggest that NFI is
important for the integration of the signaling mechanisms elicited by PACAP and
CNTF at the level of the GFAP promoter, resulting in enhancement of GFAP gene
expression when both factors are present simultaneously. To test more directly the
hypothesis that PACAP and CNTF can act together to enhance GFAP expression
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synergistically during astrocytogenesis, we carried out astrocyte differentiation
experiments using cortical precursor cells exposed to both factors.
Primary cortical precursor cells from E17 rat brains were cultured in defined
medium in the presence of bFGF for at least 24 hours after plating, and bFGF was
withdrawn prior to treatment with CNTF or with PACAP. Exposure of cells to CNTF
alone resulted in a concentration-dependent increase in the number of GFAP-positive
cells generated over a period of two days in culture (Fig. 7). The highest level of
differentiation response in terms of percentage of GFAP-positive cells relative to the
total number of cells was reached at a concentration of CNTF of 30 ng/ml (Fig. 7). As
in previous studies (Vallejo and Vallejo 2002), exposure of cells to PACAP resulted in
a concentration-dependent generation of astrocytes. The optimum concentration of
PACAP to trigger the differentiation of most cortical precursor cells is 100 nM.
Therefore, we used suboptimal concentrations of PACAP (10 nM) and CNTF (10
ng/ml) to assess the possible existence of a cooperative effect between the two agents in
promoting astrocyte differentiation.
As shown in figure 7, the exposure of cells to relatively low concentrations of
PACAP and CNTF combined resulted in an additive increase in the percentage of
GFAP-positive cells, as compared with the number of GFAP-positive cells obtained
with each agent given independently. Considering the number of differentiated cells as
the only parameter of the response, these results do not necessarily support the
conclusion that CNTF and PACAP act synergistically. However, we noticed that the
presence of both PACAP and CNTF simultaneously resulted in the generation of
GFAP-positive cells with a more elaborate morphology than cells treated with only one
of these agents independently (Fig. 8). To analyze this in detail, we treated cortical
precursor cells with different concentrations of PACAP and CNTF, alone or in
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combination, and quantified the total length of processes generated in each cell after
performing GFAP immunocytochemistry. As shown in figure 8, cells treated with either
PACAP or CNTF alone generate processes of approximately similar lengths that do not
increase in a concentration dependent manner (Fig. 8G). In contrast, when PACAP and
CNTF are present simultaneously at relatively low concentrations (10 nM and 10 ng/ml,
respectively), astrocytes generated extend cellular processes that are significantly longer
that those developed by cells treated with either PACAP or CNTF alone, even when
these agents are used at higher concentrations (Fig. 8 A-C, quantified in Fig. 8G). Even
longer processes were observed when PACAP, used at low concentration (10 nM) was
present simultaneously with CNTF at an intermediate concentration (30 ng/ml) (Fig. 8
D-F, quantified in Fig. 8G), or when PACAP, used at a high concentration (100 nM)
was present simultaneously with CNTF at a low concentration (10 ng/ml) (image not
shown, quantified in Fig. 9G). Thus, in these cases the length of the processes when
both agents are present together is higher than additive, relative to that observed with
each single factor, indicating the existence of synergism between PACAP and CNTF to
increase GFAP expression. Western immunoblot confirmed that the content of GFAP in
cells exposed to the combined treatment is higher than those observed in cells treated
with a single agent (Fig. 9).
DISCUSSION
Positive and negative regulation of GFAP gene expression - Astrocytes arise from
the same precursor cells that give rise to neurons, but relative to the generation of
neurons, the generation of astrocytes is delayed in time during brain development (Qian
et al. 2000; Gorski et al. 2002; Anthony et al. 2004). This suggests the existence of
silencing mechanisms that prevent the inappropriate expression of GFAP before the
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onset of astrogenesis. Indeed, it has been shown that stimuli that induce neuronal
differentiation trigger simultaneously the activation of inhibitory mechanisms that
prevent GFAP gene transcription (Park et al. 1999; Sun et al. 2001). Astrocytes
themselves have been recently suggested to act as progenitor cells to generate neurons
in the adult central nervous system (Doetsch et al. 1999; Heins et al. 2002), and it is
likely that during that process active repression of GFAP gene expression at the
transcriptional level occurs. In addition, it has been shown that astrocytes generated
from radial glial precursors can repress GFAP expression and revert to a radial glial
phenotype (Schmid et al. 2003).
Our results show that the GFAP gene promoter contains regions that behave as
transcriptional silencers. Thus, a significant elevation in the basal activity of the GFAP
promoter was observed with a 5’-deletion to nucleotide –1342, suggesting the existence
of negative-regulatory elements upstream from that position.
A deletion to nucleotides –1049 significantly decreased transcriptional activity,
indicating the existence of important positive-regulatory elements located between
nucleotides –1342 and –1049. However, the progressive increases in transcriptional
activity observed with further deletions to nucleotides –384 and –106 suggest the
presence of transcriptional repressor elements located between nucleotides –1049 and
–384, as well as between –384 and –106. Finally, we found that regulatory elements
located between nucleotides –106 and –35 are sufficient to yield levels of transcriptional
activity approximately similar to those observed with the full length GFAP promoter
used in these studies.
We found that NFI binds to a regulatory element located within this region, and
that integrity of this element is important for the activity of the GFAP promoter. NFI is
known to be required for cAMP-dependent inducibility of the myelin basic protein gene
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(Clarck et al. 2002), and to be directly regulated by cAMP in thyroid cells (Ortiz et al.
1999). However, although mutation of the NFI binding site significantly reduced basal
promoter activity, it did not affect induction by PACAP, which signals via cAMP
(Vallejo and Vallejo 2002), in cortical precursor cells, indicating that elements regulated
by PACAP/cAMP are independent of the NFI site. Work related to the detailed
characterization of these elements is in progress in our laboratory and will be reported
elsewhere.
Binding of NF1 to the GFAP promoter - Our data indicate the presence of the NFI-C
isoform complexed on the proximal promoter region of the GFAP gene, but other
isoforms may also be present because complexes visualized by EMSA were inhibited in
the presence of the 8199 antiserum, which recognizes all related NFI proteins, and the
antiserum used in ChIP assays does not discriminate among the different NFI isoforms.
Indeed, NFI-A has previously been detected in the mouse cortex at E15 (Shu et al.
2003), a developmental age that corresponds approximately to rat E16.5, in agreement
with our finding of increased binding to the NFI site in nuclear extracts from rat E17
cortex. The possible presence of several NFI isoforms, as well as the relative
heterogeneity of the intact fetal brain tissue used to prepare the nuclear extracts, may
have contributed to the relatively low band resolution observed in these experiments as
compared to those carried out with the RC2.E10 cell line.
The NFI family of transcription factors, encoded by at least four different genes,
comprises a complex group of related proteins that dimerize with one another
(Gronostajski, 2000). Some of these isoforms have been shown to be present in the
central nervous system (Sumner et al. 1996; Chaudhry et al. 1997; Shu et al. 2003; Gray
et al. 2004) and to regulate the expression of neural genes (Bedford et al. 1998; Clarck
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et al. 2002; Wang et al. 2004). We found that the expression of NFI proteins appears to
be practically undetectable in the cortex of E14 rat embryos. However, previous studies
have shown that several NFI gene transcripts are present in the mouse cortex from at
least E11.5 (Chaudhry et al. 1997; Shu et al. 2003). This apparent discrepancy may be
due to poor translation of NFI mRNAs early in development or to relative limitations of
the antiserum to detect specific NFI protein isoforms.
Krohn et al. (1999) reported that treatment of astrocytes with TGF-b1 results in
increased binding of nuclear proteins to the NFI site. However, binding of NFI proteins
themselves could not be demonstrated. We could not detect the presence of NFI using
the same commercial antiserum used by Krohn et al. (1999), and therefore limitations of
this reagent cannot be ruled out. Nevertheless, these authors used fully differentiated
mature astrocytes, and it is possible that in these cells treated with TGF-b1 the NFI site
may be preferentially occupied by other proteins, whereas NFI may play a more
important role in the stimulation of GFAP gene expression during astrocyte
differentiation from cortical precursor cells. In support of this notion, it should be noted
that disruption of the genes encoding NFIA or NFI-B impairs GFAP gene expression
and causes glial-cell related developmental anomalies in mice (Das Neves et al. 1999;
Shu et al. 2003; Steele-Perkins et al. 2005). Furthermore, it is noteworthy that NFI
expression increases coinciding with the onset of astrocytogenesis at around E17, and
that at this time it occupies the GFAP promoter in vivo.
At E14, cortical progenitor cells treated with PACAP (our unpublished
observations), CNTF or bone morphogenetic proteins, do not give rise to astrocytes,
because competence to respond to astrogenic signals is only gained late in development
(Mabie et al. 1999; Molné et al. 2000; Pachinsion et al. 2001; Takizawa et al. 2001).
The acquisition of competence is gained, in part, by mechanisms that involve chromatin
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remodeling induced by bFGF (Song and Ghosh 2004). It has been found that during the
process of chromatin remodeling that facilitates tissue-specific gene activation, NFI acts
early to preset the chromatin structure and stabilize the position of nucleosomes to
maintain an open chromatin conformation compatible with transcriptional activity
(Lefevre et al. 2003; Belikov et al. 2004; Vicent et al. 2004). This type of chromatin
transition induced by NFI could represent a general mechanism for determining tissue-
specific gene expression (Belikov et al. 2004).
Taken together, several of our observations are in agreement with a possible role
of NFI in participating in the promotion of an active chromatin state of the GFAP gene
prior to astrocyte differentiation. First, NFI appears to be undetectable at E14, a
developmental time in which cortical precursor cells are not competent to generate
astrocytes; second, NFI expression increases and is readily detectable at E17, a
developmental time that coincides with the onset of astrocytogenesis; third, NFI
occupies the GFAP promoter in cortical precursor cells from E17 embryos prior to the
induction of astrocyte differentiation; and fourth, prevention of binding of NFI to the
GFAP gene by mutation of the NFI site significantly impairs full activation of the
GFAP promoter by PACAP or CNTF, even though the signaling pathways that mediate
CNTF or PACAP transcriptional transactivation effects appear to be intact.
Synergism of PACAP and CNTF during astrocytogenesis - Data from transfection
experiments in primary cortical cells were interpreted bearing in mind that modest
changes in GFAP promoter activity could generate relatively large amounts of GFAP
protein that accumulate in the cells (Bonni et al. 1997). Thus, the enhanced stimulation
of the GFAP promoter by simultaneous exposure of cells to PACAP and CNTF can not
simply be explained as an additive effect, because the introduction of a mutation that
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prevents binding of NFI to the GFAP promoter, although reducing the basal activity,
does not prevent transcriptional transactivation by PACAP alone (about 8-fold) or
CNTF alone (about 6-fold), but prevents the additional enhancement observed in the
presence of both simultaneously. The notion that CNTF and PACAP cooperate to
facilitate astrocytogenesis is further supported by our finding that astrocytes generated
in the presence of both factors acquire a more elaborate morphology than those
generated by exposure to only one of them, with significantly longer processes than
expected with an additive effect, thus reflecting a higher production of GFAP as a
consequence of a synergistic interaction. Other astrogenic factors have also been found
to cooperate to facilitate astrocyte differentiation (Nakashima et al. 1999; Rajan et al.
2003).
The molecular basis for the observed synergism remains to be determined.
Ongoing experiments in our laboratory have identified a cAMP response element that
mediates PACAP-induced GFAP transactivation (Vallejo and Vallejo 2002) located
between nucleotides –106 and –35, that is distinct from the NFI binding site described
here. On the other hand, CNTF promotes astrocyte differentiation via activation of
STAT proteins that bind specific GFAP promoter elements located at a distance (Bonni
et al. 1997; Kahn et al. 1997; Rajan and McKay 1998). Therefore, it is possible that NFI
is important for the integration of independent signaling mechanisms that synergize at a
transcriptional level to facilitate GFAP gene transcription during astrocyte
differentiation. How NFI interacts with other components of this transcriptional
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FIGURE LEGENDS
Figure 1. Deletional analysis of the promoter region of the rat GFAP gene. A ,
Schematic depiction of the 5´-deletion constructs of the rat GFAP-luciferase fusion gene
used in the transfection studies. B , Relative luciferase activities elicited after
transfections of RC2.E10 cells with luciferase reporter plasmids bearing 5’-deleted
fragments of the GFAP promoter as indicated above. Values are expressed as
percentages of the activities elicited by GFAP-A7Luc, and represent the mean + s.e.m.
of at least three independent experiments carried out in duplicate.
Figure 2. NFI present in RC2.E10 cells recognizes a specific target site in the rat GFAP
gene promoter. A, B, C, Electrophoretic mobility shift assays showing the binding of
proteins present in nuclear extracts of neural RC2.E10 cells to an oligonucleotide probe
corresponding to a region of the rat GFAP promoter that contains a consensus NFI
binding site (nucleotides –85 to –61). A, Nuclear extracts were incubated in the absence
(-) or presence of a competing oligonucleotide of identical probe sequence (Comp) or in
the presence of a nonspecific competing (NSC) oligonucleotide of unrelated sequence,
each used in a 100-fold molar excess. B, Differential competitions carried out with the
addition of a 100-fold molar excess of wild type (WT) or mutated (Mut)
oligonucleotides. The sequence of the competing oligonucleotides is shown in D. C,
Binding reactions carried out in the absence (-) or presence of either normal rabbit
serum (NRS) or anti-NFI a8199 or a2902 antisera. Arrows indicate bands
corresponding to protein-DNA complexes containing NFI and to the supershifted (SS)
complexes. D, Sequence of the wild type (WT) or mutated oligonucleotides used in the
electrophoretic mobility shift assays. The consensus NFI binding site is indicated within
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a rectangle, and the nucleotides mutated are underlined. The nucleotide number relative
to the transcription initiation site is indicated on top. E, Relative luciferase activities
elicited after transfections of RC2.E10 cells with either wild type (WT) or mutated
(Mut) GFAP-A7Luc reporter plasmids. As indicated in D , the plasmid GFAP-
A7MutBLuc (Mut B) incorporates a four-bp mutation within the NFI site, whereas the
plasmid GFAP-A7MutCLuc (Mut C) incorporates a four-bp mutation immediately
downstream from the NFI site (see Fig. 2D). Values are expressed as percentages of the
activities elicited by GFAP-A7Luc, and represent the mean + s.e.m. of at least three
independent experiments carried out in duplicate.
Figure 3. Expression of NFI in primary cortical neuroepithelial precursor cells induced
to differentiate into astrocytes by exposure to PACAP. Cells were cultured in defined
medium in the presence of bFGF (20 ng/ml) for 24 hours. After this, the medium was
replaced with fresh identical medium (left panels), or with medium lacking bFGF but
containing PACAP (100 nM) (right panels). Two days after this, cells were fixed and
processed for immunocytochemistry for GFAP or NFI. Note that NFI immunoreactivity
is detected in cells both before and after astrocyte differentiation. The bottom panels
represent cells processed for NFI immunocytochemistry in the presence of an NFI-
specific blocking peptide.
Figure 4. Chromatin immunoprecipitation assays indicating the occupation of the
endogenous GFAP gene promoter by NFI present in primary cortical neuroepithelial
cells. Immunoprecipitations were carried out in the presence of anti-NFI antiserum or
control normal rabbit IgG, using undifferentiated primary cortical precursor cells
growing in the absence of PACAP (-PACAP) or astrocytes generated after exposure of
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those cells to 100 mM PACAP (+PACAP). PCR products corresponding to the region
of the GFAP gene promoter that contains the NFI binding site are shown. Specificity of
the immunoprecipitated chromatin fragment corresponding to the GFAP gene was
tested by carrying out PCR amplifications corresponding to a fragment of the promoter
of the somatostatin gene (SMS). In this case, no DNA fragment was amplified in
samples obtained after immunoprecipitation with the anti-NFI antiserum. In addition, no
DNA was amplified when Rat-1 fibroblasts were used.
Figure 5. NFI expressed during late brain development binds to the consensus NFI site
present in the rat GFAP gene promoter. A, Western immunoblot showing the expression
of NFI and GFAP in nuclear or whole cell extracts, respectively, prepared from
developing cerebral cortex of rat embryos of 14 (E14), 17 (E17) and 19 (E19) gestation
days, or from the cortex of rat pups of 1 day of postnatal age (P1). Note that NFI and
GFAP exhibit similar patterns of expression. CREB immunoreactivity was used as a
control for even loading. B, C, D, Electrophoretic mobility shift assays showing the
binding of proteins present in the nuclear extracts indicated in A to an oligonucleotide
probe corresponding to a region of the rat GFAP promoter that contains a consensus
NFI binding site (nucleotides –85 to –61). In C and D, only nuclear extracts from the
cortex of E17 rat fetuses were used. C, competitions were carried out by adding a 100-
fold molar excess of wild type (WT) or mutated (Mut) oligonucleotides. The sequences
of those oligonucleotides is indicated in Fig. 2D. The arrow indicates the presence of
protein-DNA complexes that bind to the NFI consensus site. D, Binding reactions were
carried out in the presence of either normal rabbit serum (NRS) or anti-NFI a8199 or
a2902 antisera. The arrow indicates protein-DNA complexes containing NFI that
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disappear in the presence of the a8199 antiserum, and arrowhead indicates supershifted
complexes generated in the presence of the a2902 antiserum.
Figure 6. Relative luciferase activities elicited after transfections of primary cortical
neuroepithelial precursor cells from the brains of E17 rat fetuses with either wild type
GFAP-A7Luc reporter plasmid, or a with similar plasmid that incorporates a four base
pair mutation either within (Mut B) or outside (Mut C) the NFI binding site (these
mutations correspond to those indicated in figure 2D). Transfected cells were left
untreated or were treated with PACAP, CNTF, or both. Values are expressed as
percentages of the activities elicited by GFAP-A7Luc in untreated cells, and represent
the mean + s.e.m. of at least three independent experiments carried out in duplicate.
*P<0.005; **P<0.001 (ANOVA). Differences in the activities elicited by PACAP
and/or CNTF on the Mut B plasmid were not statistically significant.
Figure 7. Generation of GFAP-expressing cells from primary cortical precursor cells
induced by PACAP and CNTF. Cortical cells from E17 rat brains were cultured in
serum-free defined medium containing 20 ng/ml bFGF. After withdrawal of bFGF, cells
were left untreated (-) or were treated for 2 days with PACAP or CNTF at the indicated
concentrations. One group of cells was exposed to 10 nM PACAP and 10 ng/ml CNTF
simultaneously. Cells were then fixed and processed for immunocytochemistry with a
monoclonal anti-GFAP antibody. The percentage of GFAP-positive cells relative to the
total number of cells per field of vision (fov) is depicted. Values represent mean +
s.e.m. of data gathered from three experiments carried out in duplicate. At least 8-10
non-overlapping fov per dish were examined.
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Figure 8. A-F, Immunocytochemical staining of GFAP in astrocytes generated from
primary precursor cells prepared form the cerebral cortex of E17 rat fetuses. To induce
astrocyte differentiation, cells were treated for two days with PACAP (10 nM), CNTF
(10 or 30 ng/ml), or both agents simultaneously used at the indicated concentrations.
Cells exposed to PACAP and CNTF simultaneously (C and F) exhibit processes that are
longer than those exhibited by cells treated with only one of them separately (A, B, D
and E). G , Quantitative representation of the average process length per cell in
astrocytes generated by treatment with PACAP, CNTF, or both together over a period
of two days, used at the indicated concentrations. Values represent mean + s.e.m. of
data gathered from three independent experiments. The total number of cells analyzed
in each condition (n) is indicated at the bottom.
Figure 9. Western immunoblot showing expression of GFAP in extracts of primary
cortical cells treated for 2 days with PACAP and/or CNTF at the concentrations (nM for
PACAP, ng/ml for CNTF) indicated on top of each lane. b-Actin immunoreactivity was
used as a control to monitor even loading.









